Approval · Notice of Compliance 1693 · 2001
HEXALEN: Notice of Compliance 1693
Issued February 15, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1693
- Date
- February 15, 2001
- Company
- Mgi Pharma Inc.Ridgefield Park, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HEXALEN | 02126230 | Cancelled Post Market |
Medicinal ingredients
- ALTRETAMINE 50 MG per CAP